XO1 Ltd.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
XO1 Ltd. - overview
Established
2013
Location
-, -, UK
Primary Industry
Pharmaceuticals
About
XO1 Ltd. develops innovative solutions designed to enhance operational efficiency across various sectors, addressing critical challenges faced by clients in high-performance industries. Founded in 2013 in the UK, XO1 Ltd. specializes in creating solutions tailored for industries that prioritize high performance and reliability.
Mohammad Abdulaal, the founder, has a history of entrepreneurial endeavors, although specific details about previous companies are not available. The company has engaged in 2 funding rounds, with the latest being a Series A round raising USD 11. 00 mn on March 19, 2015, primarily from Index Ventures. This funding has contributed to the total amount raised of USD 11.
00 mn. XO1 Ltd. offers a range of innovative products aimed at improving efficiency and effectiveness for clients in technology, healthcare, and manufacturing sectors. These products are designed to resolve operational bottlenecks and enhance scalability, serving a wide client base primarily in North America, Europe, and select Asia-Pacific regions.
The company’s offerings have gained traction for their ability to deliver measurable value to users seeking to optimize their operations. In the most recent year of 2022, XO1 Ltd. reported zero revenue and zero EBITDA, indicating no financial transactions or income during that period. Following its acquisition by Janssen Pharmaceuticals in March 2015, XO1 is strategizing future growth by developing new products aimed at enhancing operational capabilities.
The company plans to expand into new markets, targeting specific regions in Asia-Pacific, with potential launches expected in the next couple of years. The funding acquired during the Series A round is intended to support these initiatives, allowing for substantial investment in product development and market penetration.
Primary Industry
Pharmaceuticals
Sub Industries
Biopolymers, Biopharmaceuticals, Pharmaceutical Research & Development
Website
www.xo1.co.uk
Company Stage
Acquired
Total Amount Raised
Subscriber access only
XO1 Ltd. - timeline of key events
XO1 Ltd. - financials
| Fiscal Year Ended | Jul 03, 2016 | Jul 02, 2017 | Dec 31, 2017 | Dec 30, 2018 | Dec 29, 2019 | Dec 29, 2020 | Jan 03, 2021 | Jan 02, 2022 |
|---|---|---|---|---|---|---|---|---|
| Revenue (USD) | 2,900,048 | 1,639,141 | 1,061,000 | 46,000 | 2,000 | - | - | - |
| % Revenue Growth (YoY) | - | (43.5%) | - | - | (95.7%) | - | - | - |
| EBITDA (USD) | (563,260) | 4,332 | (95,000) | - | - | - | - | - |
| Operating Income (USD) | (572,015) | (2,300) | (98,000) | - | - | - | - | - |
| Operating Margin | (19.7%) | (0.1%) | (9.2%) | - | - | - | - | - |
| % EBITDA Margin | (19.4%) | 0.3% | (9.0%) | - | - | - | - | - |
| NET Income (USD) | (567,428) | 1,863 | (98,000) | - | - | - | - | - |
| % Net Margin | (19.6%) | 0.1% | (9.2%) | - | - | - | - | - |
XO1 Ltd. - employee data
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.